Friday, October 10, 2008 1:06:35 PM
http://www.medscape.com/viewarticle/581064_print
"Several biologic agents are currently approved by the US Food and Drug Administration (FDA) for the treatment of Crohn's disease: infliximab, adalimumab, certolizumab pegol, and natalizumab. It is difficult to directly compare the results of one trial with those from another because trial designs are dissimilar and each trial employs different inclusion and exclusion criteria. With this caveat in mind, the endpoints used in the various TNF antagonist trials are similar. The remission rates at weeks 26-30 for the 3 anti-TNF agents now available are very similar and range from 23% to 31%. Although natalizumab is reserved for patients who cannot tolerate or who fail to respond to an anti-TNF agent, its remission rate at week 36 is reported as 44%. Therefore, other factors in addition to efficacy must be taken into account when selecting a treatment option, so the decision must be made in consideration of patient factors."
"....on the biotech battle-field, you need some élan...."
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM